New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
07:11 EDTBMYBristol-Myers key studies still have high chance of success, says JPMorgan
JPMorgan says it still sees a high probability that Bristol-Myers' two key phase III studies of nivolumab in 2nd-line lung cancer hit their endpoints. The firm views the study results as the key catalyst for shares in the next six months, and notes its view is unchanged following this year's American Society of Clinical Oncology meeting. JPMorgan has an Overweight rating on Bristol with a $60 price target.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use